In agreement with the in vivo results, in vitro assays also demonstrates that overexpression of MYBL1 significantly enhanced sorafenib resistance compared with the vector control in HCC, which was indicated by increased numbers of colony formation cells and an increasing IC50 of sorafenib (Fig. 8B, C) (IC50 values were: HCC-Vector 4.98 μM; HCC-MYBL1 12.60 μM; Hep3B-Vector 2.87 μM; Hep3B-MYBL1 7.79 μM). The gene discussed is MYBL1; the disease is hepatocellular carcinoma.